Basically the Hexima antifungal treatment failed the phase 2b trial and the results didn't justify continued research.
https://www.biotechdaily.com.au/wp/wp-content/uploads/2022/07/BD-Biotech-Daily-Jul-11-Hexima.pdf
- Forums
- ASX - By Stock
- Ann: Appointment of Chief Scientific Officer
Basically the Hexima antifungal treatment failed the phase 2b...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AI (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
-0.001(11.1%) |
Mkt cap ! $13.49M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.8¢ | $12.19K | 1.496M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 8005858 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 1450846 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
24 | 7647858 | 0.008 |
7 | 6280009 | 0.007 |
8 | 2636750 | 0.006 |
7 | 2610009 | 0.005 |
1 | 65000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1450846 | 10 |
0.010 | 899899 | 4 |
0.011 | 2211111 | 4 |
0.012 | 1008863 | 6 |
0.013 | 1071928 | 4 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
1AI (ASX) Chart |